These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19543288)

  • 1. Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F.
    Agarwal R; Schmidt JJ; Stafford RG; Swaminathan S
    Nat Struct Mol Biol; 2009 Jul; 16(7):789-94. PubMed ID: 19543288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity.
    Schmidt JJ; Stafford RG
    Biochemistry; 2005 Mar; 44(10):4067-73. PubMed ID: 15751983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
    Arndt JW; Chai Q; Christian T; Stevens RC
    Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms of substrate recognition and specificity of botulinum neurotoxin serotype F.
    Chen S; Wan HY
    Biochem J; 2011 Jan; 433(2):277-84. PubMed ID: 21029044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of a novel botulinum neurotoxin.
    Zhang S; Masuyer G; Zhang J; Shen Y; Lundin D; Henriksson L; Miyashita SI; Martínez-Carranza M; Dong M; Stenmark P
    Nat Commun; 2017 Aug; 8():14130. PubMed ID: 28770820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution.
    Hanson MA; Stevens RC
    Nat Struct Biol; 2000 Aug; 7(8):687-92. PubMed ID: 10932255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition.
    Arndt JW; Yu W; Bi F; Stevens RC
    Biochemistry; 2005 Jul; 44(28):9574-80. PubMed ID: 16008342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design.
    Agarwal R; Binz T; Swaminathan S
    Biochemistry; 2005 Sep; 44(35):11758-65. PubMed ID: 16128577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrate recognition mechanism of VAMP/synaptobrevin-cleaving clostridial neurotoxins.
    Sikorra S; Henke T; Galli T; Binz T
    J Biol Chem; 2008 Jul; 283(30):21145-52. PubMed ID: 18511418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of botulinum protease for human VAMP family proteins.
    Yamamoto H; Ida T; Tsutsuki H; Mori M; Matsumoto T; Kohda T; Mukamoto M; Goshima N; Kozaki S; Ihara H
    Microbiol Immunol; 2012 Apr; 56(4):245-53. PubMed ID: 22289120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum Neurotoxin F Subtypes Cleaving the VAMP-2 Q
    Sikorra S; Skiba M; Dorner MB; Weisemann J; Weil M; Valdezate S; Davletov B; Rummel A; Dorner BG; Binz T
    Toxins (Basel); 2018 Aug; 10(8):. PubMed ID: 30071628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique substrate recognition by botulinum neurotoxins serotypes A and E.
    Chen S; Barbieri JT
    J Biol Chem; 2006 Apr; 281(16):10906-11. PubMed ID: 16478727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments.
    Foran P; Shone CC; Dolly JO
    Biochemistry; 1994 Dec; 33(51):15365-74. PubMed ID: 7803399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin.
    Shone CC; Roberts AK
    Eur J Biochem; 1994 Oct; 225(1):263-70. PubMed ID: 7925446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin.
    Chen S; Hall C; Barbieri JT
    J Biol Chem; 2008 Jul; 283(30):21153-9. PubMed ID: 18511417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a recombinant fluorescent substrate with cleavage sites for all botulinum neurotoxins in high-throughput screening of natural product extracts for inhibitors of serotypes A, B, and E.
    Hines HB; Kim AD; Stafford RG; Badie SS; Brueggeman EE; Newman DJ; Schmidt JJ
    Appl Environ Microbiol; 2008 Feb; 74(3):653-9. PubMed ID: 18083881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity.
    Jin R; Sikorra S; Stegmann CM; Pich A; Binz T; Brunger AT
    Biochemistry; 2007 Sep; 46(37):10685-93. PubMed ID: 17718519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different substrate recognition requirements for cleavage of synaptobrevin-2 by Clostridium baratii and Clostridium botulinum type F neurotoxins.
    Kalb SR; Baudys J; Egan C; Smith TJ; Smith LA; Pirkle JL; Barr JR
    Appl Environ Microbiol; 2011 Feb; 77(4):1301-8. PubMed ID: 21169446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B.
    Masuyer G; Beard M; Cadd VA; Chaddock JA; Acharya KR
    J Struct Biol; 2011 Apr; 174(1):52-7. PubMed ID: 21078393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity.
    Jin R; Rummel A; Binz T; Brunger AT
    Nature; 2006 Dec; 444(7122):1092-5. PubMed ID: 17167421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.